CO2024012060A2 - Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos - Google Patents

Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos

Info

Publication number
CO2024012060A2
CO2024012060A2 CONC2024/0012060A CO2024012060A CO2024012060A2 CO 2024012060 A2 CO2024012060 A2 CO 2024012060A2 CO 2024012060 A CO2024012060 A CO 2024012060A CO 2024012060 A2 CO2024012060 A2 CO 2024012060A2
Authority
CO
Colombia
Prior art keywords
apol1
methods
inhibitors
tautomers
pharmaceutically acceptable
Prior art date
Application number
CONC2024/0012060A
Other languages
English (en)
Spanish (es)
Inventor
Leslie A Dakin
Timothy J Senter
Tiansheng Wang
Haoxuan Wang
Jessica H Olsen
Akira J Shimizu
Zachary Gale-Day
Ming Chen
Sheila Namirembe
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CO2024012060A2 publication Critical patent/CO2024012060A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2024/0012060A 2022-02-08 2024-09-04 Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos CO2024012060A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263307926P 2022-02-08 2022-02-08
PCT/US2023/012583 WO2023154314A1 (en) 2022-02-08 2023-02-08 Spiro piperidine derivatives as inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
CO2024012060A2 true CO2024012060A2 (es) 2024-09-30

Family

ID=85415293

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0012060A CO2024012060A2 (es) 2022-02-08 2024-09-04 Derivados de espiro piperidina como inhibidores de apol1 y métodos para usarlos

Country Status (8)

Country Link
US (1) US20250195483A1 (cg-RX-API-DMAC7.html)
EP (1) EP4476207A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025505645A (cg-RX-API-DMAC7.html)
CN (1) CN119212986A (cg-RX-API-DMAC7.html)
AU (1) AU2023218940A1 (cg-RX-API-DMAC7.html)
CA (1) CA3251155A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024012060A2 (cg-RX-API-DMAC7.html)
WO (1) WO2023154314A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3897833T (lt) 2018-12-17 2026-04-27 Vertex Pharmaceuticals Incorporated Apol1 inhibitoriai ir jų panaudojimo būdai
EP4097083A1 (en) 2020-01-29 2022-12-07 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same
EP4146633A4 (en) 2020-05-07 2024-09-25 Rambam Med-Tech Ltd. COMPOSITION FOR USE IN THE TREATMENT OF A DISEASE ASSOCIATED WITH APOL1
JP2023530271A (ja) 2020-06-12 2023-07-14 バーテックス ファーマシューティカルズ インコーポレイテッド Apol1の阻害剤及びこれを使用する方法
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
BR112023003423A2 (pt) 2020-08-26 2023-03-21 Vertex Pharma Inibidores de apol1 e métodos de uso destes
US12612379B2 (en) 2021-11-30 2026-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8222288B2 (en) * 2006-08-30 2012-07-17 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and the uses thereof
CN101563324A (zh) * 2006-12-22 2009-10-21 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
JP2017535545A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−1,4’−ピペリジン化合物
CN108884096B (zh) * 2016-02-08 2022-03-22 豪夫迈·罗氏有限公司 作为ddr1抑制剂的螺二氢吲哚酮
US12698266B2 (en) * 2019-12-19 2026-08-04 Casma Therapeutics, Inc. TRPML modulators
US20230014907A1 (en) * 2020-06-12 2023-01-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and methods of using same

Also Published As

Publication number Publication date
AU2023218940A1 (en) 2024-08-22
US20250195483A1 (en) 2025-06-19
CA3251155A1 (en) 2023-08-17
EP4476207A1 (en) 2024-12-18
CN119212986A (zh) 2024-12-27
WO2023154314A1 (en) 2023-08-17
JP2025505645A (ja) 2025-02-28

Similar Documents

Publication Publication Date Title
CO2024012058A2 (es) Derivados de 2-metil-4’,5’-dihidrospiro[piperidina-4,7’-tieno[2,3-c]pirano] como inhibidores de apol1 y métodos de uso de los mismos
ECSP23020167A (es) Inhibidores de apol1 y métodos para usar los mismos
ECSP24050151A (es) Derivados de 4-fenil-2-(1h-1,2,3-triazol-4-il)piperidin-4-ol como inhibidores de apol1 y métodos para usar los mismos
CO2024001367A2 (es) Compuestos antivirales
UY40474A (es) Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
CL2021003202A1 (es) Compuestos de pirrolidina
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
BR112022013488A2 (pt) Pirazolo-pirimidinas substituídas e seu uso
MX2023014466A (es) Derivados de piridopirimidina útiles como inhibidores de cinasa wee1.
CO2021017202A2 (es) Compuestos tricíclicos
CL2025000672A1 (es) Compuestos derivados de aminopirimidina, inhibidores de cdk2; composición farmacéutica; uso para tratar cáncer.
CO2024010542A2 (es) Inhibidores de apol1 y métodos de uso
MX2024011755A (es) Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)
AR126892A1 (es) Compuestos de aminopiridina sustituidos como inhibidores de egfr
BR112022005706A2 (pt) Inibidores de 1,6-naftiridina substituída de cdk5
AR085905A1 (es) Una combinacion farmaceutica sinergistica para el tratamiento del cancer de pancreas
JOP20240119A1 (ar) مشتقات نافثيريدينون لمعالجة مرض أو اضطراب
WO2024220852A3 (en) Tead core inhibitors for cancer therapeutics
EA202192414A1 (ru) Соединения-ингибиторы натрий-водородного обменника 3
AR131909A1 (es) Compuestos macrocíclicos de aminopiridina como inhibidores de egfr
AR134197A1 (es) Compuestos para el tratamiento de enfermedad renal